What does IMO stand for?

Immune Modulatory Oligonucleotides

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Institute of Management, Nirma University (Ahmedabad, India) In My Not-Very-Humble Opinion Internet Marketers of New York Independent Music New Zealand I Mean Obviously I'm Moving On Icelandic Meteorological Office Idaho Mounted Orienteering (club) Im Moment (German: In This Moment) Imaobong Missionary Outreach		In Memory Of In Mijn Ogen (Dutch: in My Eyes) In My Opinion Incident Management Officer Independent Electricity Market Operator Independent Market Operator Independent Marketing Organization (insurance) Information Management Officer Information Media Outlet Infrastructure Management Outsourcing

Samples in periodicals archive:

Immune Modulatory Oligonucleotides (IMO([R])) This portfolio holds over 280 patents and patent applications worldwide covering Idera's IMO technologies and includes claims covering novel agonists of Toll-like Receptors (TLRs) 7, 8 and 9 and antagonists of TLRs 7 and 9.

Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results ...

Immune Modulatory Oligonucleotides (IMO([R])) This portfolio holds over 280 patents and patent applications worldwide covering Idera's IMO technologies, which includes claims covering novel agonists of Toll-like Receptors (TLRs) 7, 8 and 9 and antagonists of TLRs 7 and 9.

Idera Pharmaceuticals Announces Issuance of Patents Covering its ...

Intellectual Property Immune Modulatory Oligonucleotides The Company currently holds over 260 issued patents and pending patent applications world-wide covering the compositions and methods of using the Company's novel agonists and antagonists of TLR7, 8 and 9.

Idera Pharmaceuticals Reports Second Quarter 2009 Financial Results ...

The granting of patents in Europe and Australia in the field of Immune Modulatory Oligonucleotides (IMOs) that target TLRs.

Idera Pharmaceuticals Announces 2006 Financial Results for the Three ...

AMEX: IDP) today announced the granting of patents in Europe (EU 1,278,761) and Australia (AU 2001257366) on immune modulatory oligonucleotides (IMO(TM)) that target Toll-like Receptors (TLRs).

Idera Pharmaceuticals Announces the Granting of Patents on Immune ...